Twist Bioscience reported a strong fiscal third quarter with record revenue of $81.5 million, a 28% increase year-over-year, and a gross margin improvement to 43.3%. The company exceeded revenue guidance and targets for cash burn and gross margin.
Total revenue for the third quarter of fiscal 2024 grew to $81.5 million, a 28% increase compared to the same period in 2023.
Gross margin increased to 43.3% in the third quarter of fiscal 2024, up approximately 900 basis points from 34.4% in the same period last year.
The company shipped products to approximately 2,300 customers and approximately 212,000 genes during the quarter.
Twist Bioscience increased full year 2024 revenue guidance to approximately $310 million to $311 million and expects gross margin at the high end of the range at approximately 42.0%.
Twist Bioscience provided updated financial guidance for fiscal year 2024, including increased revenue expectations and gross margin.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance